Photodynamic therapy in head and neck cancer by Kamil H   Nelke et al.
Postepy Hig Med Dosw (online), 2014; 68
www.phmd.pl
Review
119
Postepy Hig Med Dosw (online), 2014; 68: 119-128
e-ISSN 1732-2693
Received:  2013.07.01
Accepted:  2013.11.28
Published:  2014.02.03
Summary
Photodynamic therapy (PDT) is a special type of treatment involving the use of a photo-
sensitizer or a photosensitizing agent along with a special type of light, which, combined 
together, induces production of a form of oxygen that is used to kill surrounding cells in 
different areas of the human body. Specification of the head and neck region requires dif-
ferent approaches due to the surrounding of vital structures. PDT can also be used to treat 
cells invaded with infections such as fungi, bacteria and viruses. The light beam placed in 
tumor sites activates locally applied drugs and kills the cancer cells. Many studies are ta-
king place in order to invent better photosensitizers, working on a larger scale and to treat 
deeply placed and larger tumors. It seems that PDT could be used as an alternative surgical 
treatment in some tumor types; however, all clinicians should be aware that the surgical 
approach is still the treatment of choice. PDT is a very accurate and effective therapy, espe-
cially in early stages of head and neck squamous cell carcinomas (HNSCC), and can greatly 
affect surgical outcomes in cancerous patients. We present a detailed review about photo-
sensitizers, their use, and therapeutic advantages and disadvantages. 
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IntroductIon
Photodynamic therapy (PDT) uses the human body’s den-
dritic cells (DC), the antigen-presenting cells which are the 
initiators and modulators of the primary immune response 
in the human body. DC are most common in skin and mu-
cous membranes and can be mature or immature. After 
DC make contact with an antigen body (virus, fungi, bac-
teria and others), they start to form peptides on their sur-
faces, and they are described later as antigen-presenting 
cells (APC). Bone marrow-derived DC are the most powerful 
APC. After DC capture one antigen, their ability to capture 
more antigens declines greatly, but also can induce many 
cytokines, such as interferonα, IL-1, IL-6, IL-7, IL-12, IL-15, 
and macrophage inflammatory protein (MIP1g). Mature 
DC induce IL-12 production, and CD40 and T cell activation. 
Mitochondrially localized sensitizers (photosensitizing 
agents) are able to induce programmed cell death (apopto-
sis). Appropriate light wavelength activates local agents and 
it is excited to its singlet state, which leads to production 
of singlet oxygen or oxyradical formation. Thanks to this, 
the cell structure changes. This cytotoxic molecular species 
results in cytotoxicity, intravascular effects that change 
blood supply to selected areas and leads to cell death. It 
seems that proper illumination and an adequate photo-
sensitizing agent that targets tissues and cells and induces 
presence of oxygen are the most valuable to achieve the 
therapeutic goal. For example, various mixtures of porphy-
rins (Photofrin) are used in different cancerous conditions. 
Another well-described agent is hypericin, which is used 
as an extract of a natural plant, Saint John’s wort, that has 
some anticancer properties and in PDT usage induces pro-
tein kinase C, and also induces peroxidation of membrane 
lipids, with decrease of cellular glutathione levels, and im-
pairs mitochondrial function.
PDT has an immune-modifying impact under sub-lethal 
conditions. Increasing PDT levels may undergo rapid cell 
death apoptosis. On the other hand, high doses induce 
passive cell death, called necrosis. PDT-treated tumor cells 
are susceptible to macrophage lysis. Biochemical pathways 
triggered by PDT immune cells are presumably the conse-
quence of oxidative stress placed upon the cell [21].
The authors’ main aim of this paper was to evaluate cur-
rent PDT advances, treatment possibilities and their in-
fluence on head and neck cancer (HNC). Because of many 
factors predicting HNC, photodynamic therapy along with 
other therapies should be taken into serious consideration 
in treatment.
PhotodynamIc theraPy
Photodynamic therapy, PDT, is minimally invasive therapy, 
used in cancer and non-oncological disorders. Because of 
many clinical indications for treatment and usage of vari-
ous light sources and light absorbents, this therapy can be 
used in different sites of the human body. A special type 
of light pipe is described by Canavesi et al., and is an in-
teresting treatment alternative [7,9]. An essential part of 
the therapy is that neither the photosensitizer nor light 
alone is cytotoxic. On the other hand, produced cytotoxic 
singlet oxygen (1O2) in the radiated field leads to cancer 
or other non-cancerous tissue death because of oxidative 
damage. Cell death is more likely related to apoptosis, but 
other mechanisms are still being discovered and are the 
focus of many scientific studies. [11,67] Usage of PDT in 
the early stage of squamous cell carcinoma of the head 
and neck (SCCHN) has a great effect on therapy; however, 
another generation of photosensitizers less absorbed by 
skin is currently being developed. 5-aminolevulinic acid 
(ALA) as a porphyrin and verteporfin as a benzoporphy-
rin, and the pheophorbide 9-hydroxypheophorbide-α (9-
HPbD), represent a new branch of lower skin photosensitiv-
ity. Studies by Chung et al. investigated the mitochondrial 
events and endoplasmic reticulum (ER) stress induced by 
9-HPbD-PDT, which led to cell apoptosis [13,77]. According 
to the authors, cells treated with 9-HPbD alone or light with 
absence of 9-HPbD suggested that 9-HPbD is very similar 
to other photosensitizers and might lead to less negative 
effects on normal healthy tissue during treatment. A study 
performed on AMC-HN-3 human head and neck carcinoma 
cells using 9-HPbD-PDT showed that the use of a higher dose 
of photosensitizer 9-HPbD-PDT from 0.59 µg/ml to 2.34 µg/
ml changed the cell mechanism from apoptosis to necrosis, 
and also showed that the intracellular localization of the 
sensitizer is essential. Photodamage seems to be more ac-
curate if mitochondria (MMP, mitochondrial membrane) 
of tumor cells are under the influence of PDT, because of 
initiating a cascade of events such as release of cytochrome 
c and activation of caspases [43]. A special type of microin-
vasive carcinoma is also an indication for treatment, and 
studies performed by Quon et al. seem to confirm that [60].
PDT has many advantages in treating head and neck cancer. 
Hung et al. investigated three human HNSCC cell lines: UM-
SCC1, UMSCC14A, UMSCC22A. Light and mitochondrial pho-
tosensitizer Pc4 and mitoferrin-2 (Mfm2) were used in the 
study focused on mitochondrial iron uptake through Mfm2-
enhanced PDT. The authors suggest that Mfm2 might be a 
biomarker of sensitivity of head and neck cancers, mostly 
because of Mfm2-dependent mitochondrial iron uptake 
that induces PDT, and cell killing [33].
Head and neck squamous cell carcinomas (HNSCC) are very 
common in the upper part of the aerodigestive tract. Se-
shadri et al. explored the potential of vascular-targeted 
(vascular-disrupting agent, VDA) therapy in HNSCC using 
5,6-dimethylxanthenone-4-acetic acid (DMXAA) on two 
HNSCC xenografts on nude mice bearing subcutaneous 
FaDu (human pharyngeal squamous cell carcinoma) and 
A253 (human submaxillary gland epidermoid carcinoma) 
[65]. Both were treated with a single dose of DMXAA, 30 mg/
kg, and after 24 hours contrast magnetic resonance MRI and 
immunohistochemistry (CD31) were performed. Studies 
showed that DMXAA decreased tumor growth and vascular 
perfusion was reduced at 78% in FaDu and 49% in A253 xeno-
grafts. This study was performed to show a greater change 
in vascularization than in tumor size, which was seen at 121
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the 30th day after treatment. However, it is necessary to be 
aware that the study was performed on implanted subcuta-
neous tumors. Another vascular-targeting agent (ZD6126) 
described by Davis et al., used in HNSCC xenografts, has 
similar properties [18]. 
Head and neck cancer along with other non-tumor-like 
disorders can not only be treated with standard radical dis-
section combined with chemoradiotherapy (CRT) but also 
alternative treatments are useful. In this case, PDT will be 
closely compared and described [19].
Therapy might consist of a photosensitizer agent or might 
be combined with other chemical substances, such as cis-
platin or carboplatin. The most common are ALA (5-ami-
nolevulinic acid, 5-ALA), methyl aminolevulinate (MAL), 
9-hydroxypheophorbide (9-HPbD), erythrosine B, porfimer 
sodium (Photofrin), Foscan (temoporfin; meta-tetrahy-
droxyphenyl chlorine, mTHPC), verteporfin (BPD, benzopor-
phyrin derivative), hyperbranched poly(ether-ester) (HPEE), 
2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH), 
and hypericin-mediated (HY). Other agents can also be used.
5-Aminolevulinic acid (ALA, 5-ALA) induces synthesis of 
porphyrin, the protoporphyrin IX (PpIX). Studies show that 
malignant tissues have accumulated PpIX, which is impor-
tant for photodynamic therapy in cancer. Allman et al. in-
vestigated the treatment of head and neck carcinoma cell 
lines with the use of ionizing radiation and PDT with the use 
of 5-ALA [4]. The authors used three cell lines from human 
squamous cell carcinoma: V134, V175, SCC-61. All cells were 
incubated in serum-free medium containing 1 mM/l 5-ALA 
and in 24 hours’ time showed an increase of fluorescence. 
Ɣ-irradiation of 8 Gy performed on three cell lines before 
3 minutes PDT cumulates the effects of therapy; however, 
cell sensitivity varies depending on the cell cycle, G1 or G2. 
For example, increased accumulation of PpIX occurs during 
S-phase and G2 phase. The authors also conclude that inter-
action between ɣ-irradiation and PDT might be complicated 
by the dose and timing of variant treatments, and still this 
combined therapy requires further investigation [13,15]. 
5-ALA is also used in oral leukoplakia treatment. Shafirst-
ein et al. additionally used a pulsed dye laser in his pilot 
study, with 585 nm light. In some cases a diode laser with 
635 nm could be used, to penetrate deeper than 1-1.5 mm 
[66]. In the study 23 patients were included, with leukopla-
kia at least 10 mm wide. 8 J/cm2 seems to be an adequate 
exposure dose in this study, although other authors have 
their own techniques [48,63]. Shafirstein also suspects that 
increased p53 levels, and decreased Ki-67 levels, are related 
to oral leukoplakia DNA damage during PDT.
In some cases a hexenyl ester of 5-ALA (5-ALA-hx) can be 
used, especially in salivary gland adenocarcinoma SGT cells. 
A study by Park et al. showed that this therapy induced ne-
crotic cell death rather than apoptosis in SGT cells, and flow 
cytometry with LDH assay seems to confirm that [59]. This 
treatment method seems to be a great alternative to the 
standard surgical approach to salivary glands.
Usage of ALA and MAL might vary depending on clinical 
cases, and also have different scales of pain. They both seem 
to have a great influence on therapy success rate.
Skin lesions and cancers, such as actinic keratosis (AK), su-
perficial basal cell carcinoma (BBC) and Bowen’s disease 
(BD), should be treated with PDT. Gaál et al. performed a 
study to evaluate the degree of treatment-associated pain 
during PDT while using 5-aminolevulinic acid (ALA) and 
methyl aminolevulinate (MAL) in different anatomical re-
gions [23]. 182 treated skin cancers consisted of 80 AK, 97 
BBC and 5 BD, and 111 of all were located in the head and 
neck region and involved the cheeks, forehead, temporal 
area, nose, auricular region, lips, scalp and neck. Accord-
ing to the study, ALA-PDT causes more pain than MAL-PDT 
treatment in the head region, and patients suffer more pain 
in AK treatment. Both ALA and MAL are very commonly 
used photosensitizers; this finding might be related to pe-
ripheral nerve endings that trigger nerve stimulation dur-
ing the procedure, and studies performed by Steinbauer et 
al. seem to confirm this. It is also worth noting that patient 
pain sensation may differ [68]. 
A different approach with ALA is applied when using it on 
a gentle and thin skin layer, such as in the eyelid.
Basal cell carcinoma (BCC) and papillomas seem to be com-
mon in eyelids; therefore various treatment techniques are 
available. According to a study by Togsyerd-Bo et al., use 
of topical methyl aminolevulinate (Metvix cream, 16%) is 
a safer, noninvasive treatment, has better cosmetic results 
and is less invasive for surrounding tissues [72]. Because of 
PDT the eyelid and eye could be damaged, but the authors 
present a different approach. After using 0.4% oxybupro-
caine, a protective ocular shield is inserted under the eyelid 
with clamps or another tool to properly fix the protective 
plate to the eyelid. Also an adhesive film covers the eye 
along with a 5 mm margin around the tumor, and an ad-
ditional light-impermeable eye patch is used. A 37 J/cm2 
diode lamp with 632 nm was used. After the procedure the 
patient used an eye patch for 24 hours and eye drops for 3 
days after therapy. This method seems to have a great suc-
cess rate, with about 75% of all 12 treated patients, but still 
more studies need to be performed in order to evaluate this 
type of treatment of very difficult tumors [74].
ALA and their ester agents are used commonly worldwide 
with a great rate of success. Nevertheless, some other en-
zymes have a great influence on PDT treatment and cell 
apoptosis.
According to Separovic et al., ceramide synthase 6 (CERS1) 
is an important enzyme taking part in apoptosis and might 
lead to apoptosis resistant cells after PDT. Therefore lev-
eling CERS1 can enhance anticancer drug properties, be-
cause CERS1 is a molecular factor regulating resistance to 
PDT [64].
He et al. studied cytotoxic and apoptotic effects of combined 
9-hydroxypheophorbide (9-HPbD)-mediated PDT and CB-122
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DCA (carboplatin) on the AMC-HN-3 human head and neck 
cancer cell line in in vitro studies [28]. CBDCA was photosen-
sitized at 37°C with 9-HPbD for 6 hours with a diode laser at 
intensity of 2.0 J/cm2 for activating 9-HPbD for 15 minutes. 
Special tests were used to measure cytotoxicity and apop-
totic cell death, which was found higher in combined PDT 
and CBDCA, but in order to avoid side effects on normal 
cells, a lower dosage of 9-HPbD should be used. Further-
more, the authors’ study on AMC-HN-3 (human head and 
neck cancer cell line) cells in vitro suggests that synergis-
tic cytotoxic combined treatment leads to increased early 
and late stages of apoptosis in cells; therefore more studies 
need to take place. 
Erythrosine B is another photosensitizer used in PDT in 
treatment of oral malignancies. The study by Garg et al. 
presents its efficacy and subcellular localization in malig-
nant (H357) and pre-malignant (DOK) oral epithelial cells. In 
the study a filament lamp with average 550 nm wavelength 
was used. According to the study both cells have the same 
uptake of erythrosine but cell killing was 80% in DOK and 
just 60% in H357 cells, which could be related to mitochon-
drial membrane accumulation predisposition. It is impor-
tant that when using high-dose PDT in DOK cells necrosis 
appeared, but apoptosis was observed at lower doses in both 
cell lines. The authors also conclude that both cells show a 
different response to treatment, and H357 cells were more 
resistant to PDT and might be related to a lower necrotic 
response in PDT [24].
It seems that mitochondrial membrane predisposition to 
accumulate different agents and their ability to process 
agents should be closely evaluated in different type of tu-
mors and tumor-like disorders, and biopsy or histology 
should be performed before treatment to properly use the 
treatment. 
A study performed on carcinomas in situ (CIS) and T1 carci-
nomas of the oral cavity and larynx using porfimer sodium 
was carried out by Rigual et al. The authors used porfimer 
sodium, 2 mg/kg intravenously 48 hours before treatment, 
with a 630 nm argon laser with a dose of 50 J/cm2 for dys-
plasia and CIS and 75 J/cm2 for carcinoma [61]. It is impor-
tant that porfimer sodium has prolonged photosensitivity. 
A study on 35 patients with 15-month follow-up showed 
that PDT with porfimer sodium has a great effect on local 
dysplasia and early carcinoma. A very important fact is that 
second primary cancer sites vary from 3 to 10% after PDT 
and most of them, according to different authors, vary in 
standard surgical procedure and after use of PDT [31]. The 
authors also conclude that the use of PDT in early oral cav-
ity dysplasia responds less well than T1 stage carcinomas, 
which is essential in proper therapy planning. 
Dysplastic lesions in the head and neck, according to Ci-
vantos, are very common in the oral cavity and laryngeal 
region. Because of multiple time PDT usage it can be used in 
primary and recurrent lesions. The author used PDT among 
patients with T1 and T2 squamous cell carcinomas (SCC) 
or dysplasia, but in advanced disease PDT was only used as 
an adjuvant treatment. In 45 treated patients, 24 had oral 
cavity tumors, with SCC in 22 cases, porfimer sodium (Pho-
tofrin) intravenously was used as a photosensitizing agent, 
and therapy was performed after 48 to 72 hours. After treat-
ment of 22 cases with SCC, 11 had a complete response, 2 
had a partial response and 9 had no response. The presented 
data showed a great success rate with use of PDT in treating 
superficial malignant or premalignant lesions, but a lower 
success rate was obtained in deeper tumors [14].
When therapy or surgery is not radical, HNC might reoc-
cur. Therefore planning before surgery is essential, and de-
scribing surgical margins should be also considered wisely. 
Recurrent head and neck cancer is always a major problem 
for both patients and doctors. In some cases after major 
surgery with chemotherapy and/or radiotherapy it is not 
possible to gain access to the recurrent cancer side. There-
fore a special type of PDT, interstitial PDT (IPDT), is more 
accurate to treat inaccessible surgical sites, because of lo-
cal fibers applied deeper into tissue. Lou et al. reported the 
use of IPDT. All studies were performed after confirmed 
biopsy of persistent or recurrent head and neck cancers 
(HNC). The studied patients were sensitized with 0.15 mg 
kg-1 intravenous mesotetrahydroxyphenyl chlorin (mTHPC, 
Foscan) and were treated 4 days later with a 652 nm diode 
laser used with four treatment fibers positioned at 1.5 cm 
intervals. With USG, MRI or MRI guidance fibers were placed 
transorally (or percutaneously) near deeper tumors (also 
near vital anatomical structures) using 20 J energy. After 
the procedure patients were scheduled for follow-ups. Lou 
et al. reported 50% tumor volume decrease with no change 
of tumor size. In a total of 45 patients, 12 patients did not 
respond to treatment with PDT, and 33 who responded had 
a median survival rate of 16 months. This method is effec-
tive for carcinomas and sarcomas, especially in inoperable 
patients, and might increase the survival rate [50]. 
In studies by Copper et al., in 29 studied patients, in 25 of 
them after use of second-generation photosensitizers such 
as meta-tetra(hydroxyphenyl)chlorin (mTHPC) (Foscan), 
complete remission of the primary tumor was achieved; 
however, 4 patients were treated with conventional ther-
apy [16].
A review of the literature by Visscher et al., concerning 
mTHPC in PDT therapy, concluded that more randomized 
studies are needed to compare the treatment efficacy; how-
ever, PDT with mTHPC seems to increase the quality of life 
(QOL) in palliative care of untreatable patients [17].
Long-term outcomes in BCC performed by Betz et al. show 
that mTHPC-PDT (FOSCAN, with a low dose of 0.05 mg/kg) 
is an effective factor in treatment. After analyzing 117 pa-
tients with 460 BBC, the success rate was 90.7%. According 
to the authors, treatment with low dosage Foscan 0.05 mg/
kg with at least 40 J/cm2 and 48 hours DLI (drug light in-
terval) has the same value of success as the conventional 
regime in treating BBC with 0.15 mg/kg, 20 J/cm2 96 hours 
DLI [6].123
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A study performed by Karakullukcu et al. describes usage 
and indications for PDT in early neoplasms of the oral cav-
ity and oropharynx. According to the study PDT is more 
accurate in areas not previously treated, but also might 
slightly improve treatment in previously treated areas. The 
total response to PDT treatment rate was 90.7%, defined 
in the study consisting of 170 patients with 226 lesions, 
where 95 were primary neoplasms. The authors tried to 
identify success rates for each group according to T stage in 
the TNM classification. During the study the authors used 
mTHPC (temoporfin, Foscan) at a dose of 0.15 mg/kg, and 
illuminated patients after 96 hours after application, with 
a laser of 652 nm wavelength and 20 J/cm3, and scheduled 
routine check-ups up to a 5-years time-frame. According to 
the authors, the success rate is dependent on T stage, and 
is related to depth of invasion not more than 5 mm [40]. 
On the other hand, persistent or recurrent NPC seems to 
have more therapeutic advantages according to Nyst et 
al., because of combining temoporfin with PDT. In a study 
performed on 22 patients, the authors concluded that this 
therapy can be used to treat recurrent or residual NPC, but 
only present in the nasopharynx [57]. 
Tongue base cancer (TBC) treated with mTHPC-PDT 
0.15 mg/kg has a high success rate. According to studies 
performed by Jerjes et al., this minimally invasive surgical 
tool is the best alternative, and compared to other tongue 
base cancer methods has lower morbidity and mortality. 
33 patients treated with recurrent tongue base carcinoma 
stage IV were involved in the study. In general anesthesia 
after ultrasound examination IPDT with use of an 18 gauge 
needle and 652 nm diode laser illumination of 20 J/cm3 was 
performed. After treatment statistical analysis was per-
formed showing that there was improvement of breathing, 
swallowing and speech (P<0.001). Treatment was tolerated 
by all patients and led to tumor shrinkage and its subse-
quent control [37,41]. The same authors discussed surgical 
and PDT margins in tumor control, and agreed that PDT 
causes much less morbidity than surgery and chemora-
diotherapy. Minimally invasive surgical oncology with PDT 
seems to be a great alternative, especially as a study on T1/
T2 oral cancer and three rounds of PDT showed a lower 
chance of mortality and morbidity [39]. Nevertheless, sur-
gical biopsies should be performed to investigate possible 
aggressive tumor growth. 
Jerjes et al. also described potentially malignant oral dis-
orders such as white and red lesions (leukoplakia, erythro-
plakia, oral lichen planus, oral submucous fibrosis, actinic 
cheilitis, xeroderma pigmentosum, Fanconi’s anemia, and 
immunodeficiency syndromes) that can be treated with 
PDT. In almost all oral cancers and squamous cell carcino-
mas, first generation photosensitizers are in use, such as 
Photofrin (porfimer sodium), 5-ALA (5-aminolevulinic acid) 
and verteporfin (BPD, benzoporphyrin derivative), and the 
second generation photosensitizer Foscan (temoporfin; me-
ta-tetrahydroxyphenyl chlorine). Oral cavity malignant and 
premalignant lesions should be treated not only surgically 
but also with PDT [36,38].
Studies performed worldwide show that oral cavity, naso-
pharynx and hypopharynx cancers have small differenc-
es in photosensitizing agent predisposition rates and this 
should also be considered before planning usage of PDT in 
the head and neck region.
Nasopharyngeal cancer cells are more sensitive to temopor-
fin compared with hematoporphyrin or merocyanine-540 
and according to Yow et al. in some cases photosensitizers 
of the first generation are less accurate to treat cancer cells; 
therefore second generation and other agents should be 
considered as useful [79,80].
Considering esophageal cancer PDT with use of talaporfin 
sodium intravenously 40 mg/m2 and diode laser of 664 nm 
with 50 J/cm2 to 100 J/cm2 was used by Yano et al. to treat 
patients with local failure to T2. After failure in chemora-
diotherapy, surgery is generally indicated; however, the 
authors claim that it has a high complication rate [10,71,78].
Oral squamous cell carcinoma (OSCC) treated with PDT 
seems to have better cosmetic and functional outcomes 
than standard surgery combined with chemo- or radio-
therapy. 121 patients with early stages of OSCC were treated 
with mTHPC (dose of 0.15 mg/kg) and use of 652 nm laser 
light. A study by Hopper et al. was performed only in tu-
mors to 0.5 cm depth, to ensure proper laser penetration 
and treatment. Treatment took place mostly on the mouth 
floor, lip, tongue and buccal mucosa, and complications 
occurred only in 6%. The most important matter is that 
the survival rate (SR) at 1 and 2 years was 89% and 75% re-
spectively. Standard retreatment using surgery repeated in 
the oral cavity is associated with scarring, tissue loss, and 
changes after radiotherapy on the oral mucosa, and leads 
to functional problems. Thanks to PDT tissue loss is smaller 
and essential functions remain unharmed, and it can be 
used regardless of patients’ age [30].
Skin tumors are also treated with PDT. According to the 
latest studies basal cell carcinoma (BCC) is almost in 85% 
of cases localized in facial skin, mostly in the periocular 
region. Studies showed that even after surgical removal 
of tumor with margins, some microscopic cells can still be 
present in surrounding tissues. Garcia et al. described two 
possible methods of treating BCC in the palpebral region, 
using PDT and alternative treatment with use of biological 
response modifiers such as imiquimod (IMQ). Minimally 
invasive treatments are being considered, mostly because 
BCC shows less possibility of malignancy and to avoid great 
tissue loss in the facial region. PDT in BCC mostly requires 
application of methyl aminolevulinate cream over tumor 
lesions and surrounding tissues, and leads to better esthetic 
results and a better treatment rate [51,62,70].
Karakullukcu et al. in 2013 performed a one-institute expe-
rience study describing the approach to PDT in 55 patients 
and in standard surgery in 43 patients as an alternative for 
patients with early stage oral cavity cancers, but with le-
sions thinner than 5 mm. According to the authors, over-
all survival was 83 and 75% for PDT and surgery groups, 124
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but in the PDT group 11%, and the surgical group 26% of 
patients had additional treatments. It seems that tumors 
of the tongue and mouth floor are more sensitive to PDT 
therapy than other oral sites [29]. The authors in their 
study conclude that PDT in early local stage squamous 
cell cancer of the oral cavity shows comparable rates of 
control to trans-oral resection, and furthermore PDT can 
be performed using local analgesia, while radical surgi-
cal excision requires general anesthesia. This might be 
an alternative way of treatment of patients with lesions 
smaller than 5 mm, suffering from early stages of oral cav-
ity cancers, but only if careful and scheduled work-up is 
performed. Especially oral leukoplakia and erythroplakia 
are in favor of PDT [42].
Nasopharyngeal carcinomas (NPC) in some cases are very 
hard to properly evaluate and treat. Fang et al. describe 
PDT while using apoptin, an apoptosis-inducing protein. A 
study measuring the expression of apoptin in CNE-2 NPC 
cells showed that combined PDT-apoptin treatment leads to 
a stronger therapeutic effect, and induces cell apoptosis and 
several changes in tumor cells. This study might indicate a 
better alternative to treatment than only use of PDT [20].
Special types of agents are HPPH and HPEE, which could be 
used in a combined treatment or alone, and it seems that 
most pharyngeal and esophageal diseases are sensitive to 
this type of PDT treatment. 
Li et al. reported usage of hyperbranched poly(ether-ester) 
(HPEE)-ce6 nanoparticles, and their use in CAL-27 cancer 
cells of the tongue. The assay trial showed that higher pho-
totoxicity can be achieved using 12J/cm2 of 660 nm laser 
illumination. HPEE is the newest class of macromolecule, 
characterized by many hydroxyl and carboxyl functional 
groups important in therapy, and could be a great PDT drug 
carrier. Other studies involving hyperbranched polymers 
should be performed. It seems that cell-targeted photody-
namic nanomedicine will soon be the future of the HNSCC 
treatment protocol [45,52].
A clinical trial using HPPH-PDT was performed by Sunar 
et al. to evaluate blood flow, oxygenation, and HPPH pho-
tobleaching measured after and before treatment. Accord-
ing to trial studies, the drug is strongly photobleaching 
and blood flow reduction was essential along with reduced 
oxygenation. The authors also advise the use of non-inva-
sive diffuse optical spectroscopy in patients with head and 
neck cancer. In study additionally a biopsy-based molecu-
lar marker was used, in order to evaluate photodynamic 
efficiency [69]. 
HPPH (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a) 
can also be used in Barrett’s esophagus (adenocarcinoma, 
BE) treatment with PDT. Nava et al. after using porfimer 
sodium and a light dose of 150 J/cm at 48 hours and 3-4 
mg/m2 of HPPH achieved complete study success at 72% 
at 1 year in high-grade dysplasia and early carcinomas of 
the esophagus. HPPH-PDT seems to be a safe and promis-
ing treatment of Barrett’s esophagus [55]. 
Studies performed on mice by Gil et al. showed that com-
bined PDT with oncolytic vaccinia virus (OVV) has a pos-
itive effect on treatment of primary and metastatic tu-
mors. The authors used 2-[I-hexyloxyethyl-]-2-devinyl 
pyropheophorbide-a (a second generation sensitizer) 
(HPPH)-sensitized PDT along with oncolytic virotherapy 
in nude mice with implanted syngenic murine NXS2 neu-
roblastoma and human FaDu head and neck squamous cell 
carcinoma [27]. Tumor growth and survival were mea-
sured, and MRI with immunohistochemistry was used to 
evaluate vascular function. Studies show that combined 
PDT with OVV leads to inhibition of metastatic tumor 
growth and also on the fifth study day a loss of blood flow 
to the interior of the tumor was diagnosed and cumulated 
neutrophil infiltration was noted. It seems that combined 
treatment is a better alternative than standard PDT, but 
further studies need to be made [47,58]. 
Also plants and trees naturally accessible in the environ-
ment can be used in various treatments.
Hypericin-mediated photodynamic therapy (HY-PDT) pre-
sented by Wang et al. is described as a potential way of 
treating tumors and nonmalignant disorders in the naso-
pharynx. Hypericin (HY; 1,3,4,6,8,13-hexahydroxy-10,11-
dimethyl-phenanthro [1,10,9,8-opqra]perylene-7,14-dione) 
is isolated from the plant Hypericum perforatum [75]. Studies 
involving CNE-2 cells, intracellular caspase, genome-wide 
expression and cytology tests indicate that HY-PDT ther-
apy could inhibit growth of CNE-2 cells and induce their 
apoptosis. Because of the highly destructive effect of HY-
PDT on the mitochondrial membrane, induced apoptosis 
is used in various carcinomas, and also activates cysteine-
type endopeptidase, which stops cell growth and stimulates 
apoptosis [1,2,3,14].
Hypericin and the photosensitizer liposomal meso-tetrahy-
droxyphenyl chlorin derivative (Foslipos(®)) was used in a 
study performed by Besic Gyenge, showing that combined 
therapy with both photosensitizers can decrease its tox-
icity, which can be advantageous in PDT treatments [26].
Dihydroceramide desaturase 1 (DES) is the enzyme respon-
sible for converting dihydroceramide into ceramide, and 
according to Breen is a potential molecular target for regu-
lating apoptotic resistance to PDT [8].
Thanks to TNM assessment it is quite easy to evaluate can-
cer state and special treatments are planned. PDT might be 
useful; however, the upper limit as an indication for treat-
ment with PDT related to TNM is still under consideration.
Furthermore, an extraordinary case of stage T4 nasopha-
ryngeal cancer was described by Indrasari et al. after usage 
of PDT as a factor of long-term cell response. After 5 years of 
follow-up the authors reported that the patient’s condition 
was very good and was still being carefully monitored [34].
Not only a special photosensitizing agent is needed to 
achieve proper therapeutic results, but also diagnostic 125
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tools, and proper illumination of treated head and neck 
areas. Special tomographic and MRI protocols are further 
investigated in order to provide an adequate dose and ap-
ply agents near tumor sites.
The review of the literature performed by Wildeman et al., 
referring to PDT in patients with recurrent nasopharyn-
geal carcinoma, revealed that less invasive treatment then 
surgery leads to less complications and morbidity [77]. All 
authors agreed that illumination of the nasopharyngeal 
cavity requires special techniques. For example, Nyst built 
a special device that could be easily placed in the upper 
nasopharyngeal site [56]. 
Jäger et al. suggested that a special MRI image-guided study 
is necessary to properly place the IPDT fibers in recurrent 
head and neck cancers. Patients who were treated with IPDT 
had previous surgery, radio and chemotherapy or standard 
treatment limitations, and therefore according to the au-
thors were deemed unsuitable for further surgery [35]. The 
authors used mTHPC applied intravenously for sensitization 
and 4 days before IPDT had a daily lighting setting which 
was increased every 100 lx (60-W) every day. 18-gauge MR-
compatible needles were placed in tumor sites according to 
three-dimensional planes, and due to MRI-guided needles 
were placed safely and deep into the tumor site. From 4 to 8 
days after IPDT contrast-enhanced images were performed 
in order to properly evaluate tumor necrosis, reduction and 
success of treatment. It is essential to evaluate IPDT because 
in some cases additional procedures are necessary. All au-
thors claim that still the prognosis for patients with head 
and neck tumors remains a mystery, although early stages 
can be cured [32].
Another author observed that proper deposition into deeper 
structures requires special imaging tools. Mo et al. described 
usage of fluorescence diffuse optical tomography (TD-
FDOT) with use of a photosensitizer, 2-(1-hexyloxyethyl)-
2-devinyl pyropheophorbide-a (HPPH). The study was per-
formed during simultaneous reconstruction of fluorescence 
yield and lifetime of HPPH was performed before and after 
PDT. Depth imaging was achieved through three-dimen-
sional mappings of fluorescence and tomographic stud-
ies. Studies performed on mice showed that fluorescence 
changed during time and HPPH accumulated in the tumor 
24 hours after injection [53]. 
Photosensitizing agents could also be made from natural 
herbs or plants or made from modified silica or other sub-
stances.
Lim et al. described a naturally produced photosensitiz-
er, 151-hydroxypurpurin-7-lactone ethyl methyl diester 
(compound 1) from an Araceae plant and it is compared to 
pheophorbide-a (Pha) used in head and neck cancer thera-
pies. Research was performed on HSC2 (oral cavity), HSC3 
(tongue) and nasopharyngeal HK1 and C666-1 cancer cell 
lines. Studies showed that compound 1 induced more apop-
tosis and was more accurate especially in G2/M cell cycle 
block [46].
On the other hand, Uppal et al. presented Rose Bengal, an 
anionic photosensitizer from organically modified silica 
nanoparticles with 3-amino propyl groups. The study was 
performed on oral (4451) and breast (MCF-7) cancer cells, 
and showed that Rose Bengal is less phototoxic, but modi-
fied with silica nanoplates with 3-amino propyl groups 
(FTIR) has greater phototoxicity [73]. 
conclusIons
Because of targeting only pathological cells, normal struc-
tures are unharmed. Light length about 630-650 nm com-
bined with local photosensitizers is the right choice of treat-
ment; however, greater length of light is more accurate 
only if combined with different photosensitizers applied 
intravenously [22]. Usage of 5-aminolevulinic acid (5-ALA) 
or its derivatives seems to be adequate for dermatological 
diseases, such as malignant skin lesions, Bowen’s disease, 
actinic keratosis, basal cell carcinomas and some types of 
inflammatory dermatosis. 
Lee and Moon described experimental therapeutics for 
head and neck cancer. It seems that early detection and 
proper diagnosis is a key to success. Because of treat-
ment limitations in head and neck regions, major sur-
gery is the way of choice. In most cases squamous cell 
carcinomas of head and neck (SCCHN) treatment con-
sisted of a combination of surgery with either chemo-, 
radiotherapy or both. Authors describe other possible 
therapies, such as monoclonal antibodies, molecular 
inhibitors, gene therapy and photodynamic therapy. 
It seems that targeted therapy in patients with SCCHN 
might be important in the future, along with combined 
therapy, which might lead to overcoming some basic 
surgical limitations [44].
PDT can also be used in other regions of the human 
body, not only in the head and neck. Many studies con-
cern usage in esophageal cancer and Moighissi’s study 
seems to confirm it. Early stage esophageal cancer not 
treated surgically is a good group for potential PDT us-
age, but still no accurate randomized trials have been 
performed [54]. 
Studies worldwide are taking place in order to fully de-
scribe the pathology and mechanism of human head and 
neck cancer cells [12]. 
It is also essential to remember that dosage of photosen-
sitizer should be related to the variety of light wavelength 
that should be used carefully in different regions.
Different authors report different PDT success rates 
[7,18,49]. PDT is a great alternative for standard surgery 
but requires special diagnostic tools with a photosensi-
tizer working in various limits. Because of many tumors 
and tumor-like disorders in the head and neck PDT should 
be considered as favorable in the first stage of treatment; 
however, without first performing biopsy and histological 
evaluation, use of this therapy is in vain [25,81].126
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